How BioNTech went from a little-known biotech company to creating the Covid vaccine


In this article

It was Jan. 24, 2020 when BioNTech CEO Uğur Şahin knew that Covid-19 was likely to become a global pandemic. 

Though it was over a month and a half before the World Health Organization officially declared a pandemic, Sahin met with his wife, BioNTech’s co-founder and chief medical officer Özlem Türeci. Together, they agreed to redirect most of the company’s resources to developing a vaccine. 

“He approached me and explained his thoughts and his his fears,” Türeci said. “And it was immediately clear to both of us that the technology we had, and which we had already clinically developed, that could help to ensure a rapid response.”

Up until that point, BioNTech was primarily focused on developing novel cancer treatments. The company was little-known internationally. But the founders were confident in the potential of their mRNA technology, which they knew could trigger a powerful immune response. BioNTech knew that to successfully produce, test and manufacture a Covid vaccine on a global scale, it would need a bigger partner. The company already had a relationship with Pfizer, having worked with them since 2018 to develop an mRNA-based flu vaccine, which is in clinical trials. So, BioNTech turned to them.

The companies succeeded. In August, the Pfizer-BioNTech vaccine became the first to gain full FDA approval.

Watch the video to learn about the rise of BioNTech.

Products You May Like

Articles You May Like

DocuSign plunges almost 30% after e-signature company issues weak fourth-quarter guidance
Here are some money-saving tips for re-stocking your wardrobe as you head back to the office
24% of Americans say switching jobs is the best way to boost income. Here’s when to put yourself on the market
Dow futures down more than 400 points on omicron Covid uncertainty
Pfizer CEO confident Covid treatment pill will be effective against omicron variant

Leave a Reply

Your email address will not be published. Required fields are marked *